Published in J Natl Cancer Inst on April 28, 2009
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol (2010) 2.48
Drugging topoisomerases: lessons and challenges. ACS Chem Biol (2013) 2.46
Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer (2011) 2.01
High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res (2010) 1.62
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res (2012) 1.47
Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst (2009) 1.47
CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D. Breast Cancer Res Treat (2010) 1.46
Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers. J Natl Cancer Inst (2009) 1.38
Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol (2010) 1.36
Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res (2012) 1.13
Multiplicities in cancer research: ubiquitous and necessary evils. J Natl Cancer Inst (2012) 1.07
Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. Breast Cancer Res (2011) 1.06
Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. Am J Pathol (2011) 1.02
Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens. Curr Pharmacogenomics Person Med (2009) 0.99
The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers. Curr Oncol (2009) 0.98
The important molecular markers on chromosome 17 and their clinical impact in breast cancer. Int J Mol Sci (2011) 0.93
HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. J Transl Med (2012) 0.89
Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab. J Transl Med (2012) 0.88
Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer. J Cancer Res Clin Oncol (2010) 0.88
The role of antioxidants in the era of cardio‑oncology. Cancer Chemother Pharmacol (2013) 0.84
Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs. Cancer Res (2012) 0.84
Multiplication of Chromosome 17 Centromere Is Associated with Prognosis in Patients with Invasive Breast Cancers Exhibiting Normal HER2 and TOP2A Status. J Breast Cancer (2012) 0.83
Genetic characterization of breast cancer and implications for clinical management. J Cell Mol Med (2009) 0.81
Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer. Oncologist (2012) 0.81
TOP2A amplification and overexpression in hepatocellular carcinoma tissues. Biomed Res Int (2015) 0.80
Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer. Onco Targets Ther (2014) 0.78
Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. Oncotarget (2016) 0.78
Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer. Neoplasia (2014) 0.78
Potential utility of an expression array signature for predicting anthracycline responsiveness or resistance. J Clin Oncol (2011) 0.76
O(6)-methylguanine-DNA methyltransferase as a prognostic and predictive marker for basal-like breast cancer treated with cyclophosphamide-based chemotherapy. Oncol Lett (2014) 0.76
Role of Topoisomerases in Pediatric High Grade Osteosarcomas: TOP2A Gene Is One of the Unique Molecular Biomarkers of Chemoresponse. Cancers (Basel) (2013) 0.75
Tailored targeted therapy for all: a realistic and worthwhile objective against. Breast Cancer Res (2009) 0.75
Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer. Int J Nanomedicine (2016) 0.75
Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer. Medicine (Baltimore) (2017) 0.75
Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential. BMC Syst Biol (2015) 0.75
Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients. Eur J Cancer (2017) 0.75
Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors. PLoS One (2017) 0.75
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87
HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med (2006) 5.10
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst (2007) 4.14
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res (2005) 2.60
HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol (2008) 2.46
Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer (1999) 1.82
Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer (2004) 1.49
HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res Treat (2007) 1.38
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat (2004) 1.12
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med (2001) 7.59
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med (1995) 6.86
The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol (1995) 6.08
MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell (1996) 4.13
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol (2005) 3.62
Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med (1993) 3.61
Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med (1997) 3.57
Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet (1994) 3.51
Limitations of impedance plethysmography in the diagnosis of clinically suspected deep-vein thrombosis. Ann Intern Med (1993) 3.40
Gene expression profiling of cells, tissues, and developmental stages of the nematode C. elegans. Cold Spring Harb Symp Quant Biol (2003) 3.22
Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A (1990) 3.03
Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol (2002) 2.99
Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet (2008) 2.91
Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases. Lancet (1998) 2.75
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet (2015) 2.70
Prevention of venous thromboembolism. Chest (1995) 2.69
A standard heparin nomogram for the management of heparin therapy. Arch Intern Med (1991) 2.69
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol (2014) 2.50
Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet (1997) 2.33
Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol (1999) 2.29
Responsiveness and validity in health status measurement: a clarification. J Clin Epidemiol (1989) 2.22
Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet (2012) 2.06
Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback. J Clin Oncol (1998) 1.97
Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol (1988) 1.93
Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol (1999) 1.92
A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer (2001) 1.91
Patients' preferences for therapy in advanced epithelial ovarian cancer: development, testing, and application of a bedside decision instrument. Gynecol Oncol (1996) 1.91
Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. J Natl Cancer Inst (1992) 1.87
Prevention of venous thromboembolism. Chest (1992) 1.81
Familial posterior fossa brain tumors of infancy secondary to germline mutation of the hSNF5 gene. Am J Hum Genet (2000) 1.80
Low molecular weight heparin. Blood (1992) 1.74
Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol (1986) 1.73
p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. J Natl Cancer Inst (2001) 1.67
A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med (1986) 1.67
Breast irradiation postlumpectomy: development and evaluation of a decision instrument. J Clin Oncol (1995) 1.66
Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations. Br J Cancer (2010) 1.65
Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol (2011) 1.64
A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women. Breast Cancer Res Treat (2009) 1.63
A randomized trial on the efficacy of an autologous blood drainage and transfusion device in patients undergoing elective knee arthroplasty. Transfusion (1992) 1.62
Isolation of human cDNAs for asparagine synthetase and expression in Jensen rat sarcoma cells. Mol Cell Biol (1987) 1.61
EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J Clin Oncol (1999) 1.58
Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet (1984) 1.56
Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet (1997) 1.55
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst (2010) 1.55
Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol (1987) 1.53
Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol (2002) 1.50
The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med (2001) 1.45
Systemic adjuvant therapy for node-negative breast cancer. CMAJ (1989) 1.42
Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different? J Clin Oncol (1999) 1.40
Effect of indomethacin plus ranitidine in advanced melanoma patients on high-dose interleukin-2. Lancet (1992) 1.40
Phase II study of oral menogaril as first line chemotherapy for advanced breast cancer: a National Cancer Institute of Canada Clinical Trials Group study. Ann Oncol (1992) 1.39
The HER-2/neu oncogene in breast cancer: so what is new? J Clin Oncol (1992) 1.39
Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. J Natl Cancer Inst (1999) 1.38
Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. Curr Oncol (2012) 1.37
The Colon Health and Life-Long Exercise Change trial: a randomized trial of the National Cancer Institute of Canada Clinical Trials Group. Curr Oncol (2008) 1.37
The supportive care needs of newly diagnosed cancer patients attending a regional cancer center. Cancer (1997) 1.35
Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry. Hum Mutat (2006) 1.34
Epidemiology of thrombosis in cancer. Acta Haematol (2001) 1.33
Communicating quality of life information to cancer patients: a study of six presentation formats. J Clin Oncol (2005) 1.31
The frequency of malignant neoplasms in patients with polymyositis-dermatomyositis. A controlled study. Arch Intern Med (1985) 1.28
Analysis of alterations in the retinoblastoma gene and tumor grade in bone and soft-tissue sarcomas. J Natl Cancer Inst (1991) 1.28
Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet (1987) 1.25
Asparaginyl-tRNA aminoacylation levels and asparagine synthetase expression in cultured Chinese hamster ovary cells. J Biol Chem (1979) 1.25
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol (2008) 1.24
Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol (2002) 1.21
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Ann Oncol (2010) 1.14
PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost (2010) 1.12
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. Br J Cancer (2012) 1.12
Hemorrhagic complications of anticoagulant treatment. Chest (1995) 1.10
Hemorrhagic complications of anticoagulant therapy. Semin Thromb Hemost (1986) 1.10
A role for asparaginyl-tRNA in the regulation of asparagine synthetase in a mammalian cell line. Proc Natl Acad Sci U S A (1977) 1.09
Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas. Oncogene (1999) 1.09
Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet (1995) 1.08
The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol (2005) 1.08
Mucormycosis of the tibia: a case report and review of the literature. Clin Orthop Relat Res (2000) 1.08
Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. A randomized trial. Ann Intern Med (1987) 1.08
Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer. J Med Genet (2005) 1.08
Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol (1998) 1.07
Factors affecting distant disease-free survival for primary invasive breast cancer: use of a log-normal survival model. Ann Surg Oncol (2000) 1.06
Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. Cancer (2001) 1.06
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol (2012) 1.05
Analysis of mRNA from microdissected frozen tissue sections without RNA isolation. Am J Pathol (1998) 1.05
Insulin-like growth factor 1 (IGF-1) receptors, IGF-1, and IGF-2 are expressed in primary human sarcomas. Cancer Res (1995) 1.04